Clinical Trial Update: QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1/PD-L1 Antibody Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for QL1706 in recurrent and metastatic cervical cancer resistant to prior PD-1/PD-L1 therapy. The study is currently not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Adenocarcinoma
• Cervical Cancer
• Cervical Squamous Cell Carcinoma

Drugs mentioned

• QL1706

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Cervical Cancer, Cervical Cancer Metastatic | Phase 2 | Status: NOT_YET_RECRUITING